Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurodegeneration in Late-life Depression
NCT03430869Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Mar 2018
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Standard Uptake Value Ratio of 18F-florbetapir at 3 years. Started Mar 2018; status: completed.
Beyond the preview
Go deeper on NCT03430869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430869.